To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have HER2 mutation-positive solid tumors that cannot be cured using standard therapies. These include (but are not limited to) bladder, colorectal, endometrial, gastric/esophageal, and ovarian cancers.
- At least 2 weeks must have passed since completion of prior therapies and entry into the study.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- This study is open to patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. David Solit at 646-422-4459 or Dr. David Hyman at 646-888-4544.